Nonsteroidal antiinflammatory drugs and prostaglandin E2 modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis

Arthritis and Rheumatism

Volumn 62, Issue 2, 2010, Pages 478-488

  Moreno Rubio, Juan ^a   Herrero Beaumont, Gabriel ^a   Tardío, Lidia ^a   Álvarez Soria, M Ángeles ^a   Largo, Raquel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2;

ARTICLE; BONE METABOLISM; CARTILAGE; CARTILAGE CELL; CELL MEMBRANE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; HUMAN; KNEE ARTHROPLASTY; KNEE OSTEOARTHRITIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; OSTEOARTHRITIS, KNEE; OSTEOPROTEGERIN; PYRAZOLES; RANK LIGAND; RECEPTORS, PROSTAGLANDIN E; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 75749128263     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27204     Document Type: Article

References (52)

1. Calvo E, Castaneda S, Largo R, Fernandez-Valle ME, Rodriguez-Salvanes F, Herrero-Beaumont G. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage 2007;15:69-77.
2. Kamibayashi L, Wyss UP, Cooke TD, Zee B. Trabecular micro-structure in the medial condyle of the proximal tibia of patients with knee osteoarthritis. Bone 1995;17:27-35.
3. Beuf O, Ghosh S, Newitt DC, Link TM, Steinbach L, Ries M, et al. Magnetic resonance imaging of normal and osteoarthritic trabecular bone structure in the human knee. Arthritis Rheum 2002;46: 385-93.
4. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong le T. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006;38: 234-43.
5. Kadri A, Ea HK, Bazille C, Hannouche D, Liote F, Cohen-Solal ME. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008;58:2379-86.
6. Pastoureau P, Chomel A, Bonnet J. Evidence of early subchondral bone changes in the meniscectomized guinea pig: a densitometric study using dual-energy x-ray absorptiometry subregional analysis. Osteoarthritis Cartilage 1999;7:466-73.
7. Ratcliffe A, Seibel MJ. Biochemical markers of osteoarthritis. Curr Opin Rheumatol 1990;2:770-6.
8. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206.
9. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Sem Arthritis Rheum 2003;33: 155-67.
10. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 2005;44:7-16.
11. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 2004;427(Suppl):S37-S46.
12. DiBattista JA, Pelletier JP, Zafarullah M, Fujimoto N, Obata K, Martel-Pelletier J. Coordinate regulation of matrix metalloproteases and tissue inhibitor of metalloproteinase expression in human synovial fibroblasts. J Rheumatol 1995;43:123-8.
13. Mastbergen SC, Lafeber FP, Bijlsma JW. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 2002;41:801-8.
14. El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 2003;30:2444-51.
15. Mastbergen SC, Bijlsma JW, Lafeber FP. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 2005;13: 519-26.
16. Hofbauer LC, Heufelder AE. Role of receptor activation of nuclear factor-ΚB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
17. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
18. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, et al. Localization of RANKL (receptor activator of NF ΚB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999;25:525-34.
19. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, et al. The osteoprotegerin/receptor activator of nuclear factor ΚB/receptor activator of nuclear factor ΚB ligand system in cartilage. Arthritis Rheum 2001;44:2768-76.
20. Kwan Tat S, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor ΚB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008;26:295-304.
21. Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Duval N, Martel-Pelletier J. Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone 2008;43:284-91.
22. Alvarez-Soria MA, Largo R, Santillana J, Sanchez-Pernaute O, Calvo E, Hernandez M, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006;65:998-1005.
23. Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana S, Egido J, et al. Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 2008;16:1484-93.
24. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
25. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, et al. Glucosamine inhibits IL-1β-induced NFΚB activation. Osteoarthritis Cartilage 2003;11:290-8.
26. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
27. De Gortazar A, Alonso V, Alvarez-Arroyo MV, Esbrit P. Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 2006;79:360-9.
28. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-502.
29. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139:4743-6.
30. Usui M, Xing L, Drissi H, Zuscik M, O'Keefe R, Chen D, et al. Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res 2008;23:314-25.
31. Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006;54:76-81.
32. Haynes D, Crotti T, Weedon H, Slavotinek J, Au V, Coleman M, et al. Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum 2008;59:911-20.
33. Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, et al. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum 2006;54:1463-72.
34. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor ΚB, osteoprotegerin, and receptor activator of nuclear factor ΚB ligand. Arthritis Rheum 2004;50:3831-43.
35. Wei X, Zhang X, Zuscik MJ, Drissi MH, Schwarz EM, O'Keefe RJ. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res 2005;20:1136-48.
36. 2 on osteoclastogenesis via the OPG/RANKL/RANK system. Ann N Y Acad Sci 2006;1068: 225-33.
37. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-ΚB ligand and support osteoclast differentiation. J Bone Miner Res 2000;15:1459-66.
38. 2 on gene expression in primary osteoblastic cells from prostaglandin receptor knock out mice. Bone 2002;30: 567-73.
39. 2 receptor E4-knockout mice. J Biol Chem 2000;275: 19819-23.
40. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonist for the respective EPs. Endocrinology 2000;141: 1554-9.
41. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 1999;7:419-21.
42. Samadfam R, Gallant MA, Miousse MC, Parent JL, de Brum-Fernandes AJ. Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures. J Rheumatol 2006;33:1167-75.
43. Niki Y, Takaishi H, Takito J, Miyamoto T, Kosaki N, Matsumoto H, et al. Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1α transgenic mice due to GM-CSF overproduction. J Immunol 2007;179: 639-46.
44. Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM, et al. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 2000;141: 2054-61.
45. Breuil V, Schmid-Antomarchi H, Schmid-Alliana A, Rezzonico R, Euller-Ziegler L, Rossi B. The receptor activator of nuclear factor (NF)-ΚB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J 2003;17:1751-3.
46. Mosheimer BA, Kaneider NC, Feistritzer C, Sturn DH, Wiedermann CJ. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 2004;50:2309-16.
47. Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K, et al. Vascular endothelial growth factor isoforms and their receptors are expressed in uman osteoarthritic cartilage. Am J Pathol 2003;162:171-81.
48. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009;12:35-46.
49. Min JK, Cho YL, Choi JH, Kim Y, Kim JH, Yu YS, et al. Receptor activator of nuclear factor (NF)-κB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 2007;109:1495-502.
50. Saito I, Koshino T, Nakashima K, Uesugi M, Saito T. Increased cellular infiltrate in inflammatory synovia of osteoarthritic knees. Osteoarthritis Cartilage 2002;10:156-62.
51. Adamopoulos IE, Sabokbar A, Wordsworth BP, Carr A, Ferguson DJ, Athanasou NA. Synovial fluid macrophages are capable of osteoclast formation and resorption. J Pathol 2006;208:35-43.
52. Andersson MK, Lundberg P, Ohlin A, Perry MJ, Lie A, Stark A, et al. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients. Arthritis Res Ther 2007;9:R18.